- Home
- ONDS vs SLN Comparison
ONDS vs SLN Comparison
Compare ONDS & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONDS
- SLN
- Stock Information
- Founded
- ONDS 2014
- SLN 1994
- Country
- ONDS United States
- SLN United Kingdom
- Employees
- ONDS N/A
- SLN N/A
- Industry
- ONDS Telecommunications Equipment
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- ONDS Telecommunications
- SLN Health Care
- Exchange
- ONDS Nasdaq
- SLN Nasdaq
- Market Cap
- ONDS 326.8M
- SLN 299.4M
- IPO Year
- ONDS N/A
- SLN N/A
- Fundamental
- Price
- ONDS $4.50
- SLN $5.35
- Analyst Decision
- ONDS Strong Buy
- SLN Buy
- Analyst Count
- ONDS 3
- SLN 5
- Target Price
- ONDS $4.67
- SLN $32.60
- AVG Volume (30 Days)
- ONDS 41.6M
- SLN 70.5K
- Earning Date
- ONDS 08-12-2025
- SLN 08-07-2025
- Dividend Yield
- ONDS N/A
- SLN N/A
- EPS Growth
- ONDS N/A
- SLN N/A
- EPS
- ONDS N/A
- SLN N/A
- Revenue
- ONDS $16,131,404.00
- SLN $27,169,000.00
- Revenue This Year
- ONDS $243.38
- SLN N/A
- Revenue Next Year
- ONDS $133.25
- SLN N/A
- P/E Ratio
- ONDS N/A
- SLN N/A
- Revenue Growth
- ONDS 75.16
- SLN 22.28
- 52 Week Low
- ONDS $0.57
- SLN $1.97
- 52 Week High
- ONDS $4.50
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- ONDS 69.52
- SLN 43.16
- Support Level
- ONDS $3.20
- SLN $5.14
- Resistance Level
- ONDS $4.33
- SLN $5.96
- Average True Range (ATR)
- ONDS 0.49
- SLN 0.53
- MACD
- ONDS 0.04
- SLN -0.02
- Stochastic Oscillator
- ONDS 99.41
- SLN 51.82
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.